Suppr超能文献

将香叶基香叶基二磷酸合酶与细胞存活和增殖联系起来的分子机制。

Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation.

作者信息

Agabiti Sherry S, Liang Yilan, Wiemer Andrew J

机构信息

a Department of Pharmaceutical Sciences , University of Connecticut , Storrs , CT , USA.

b Institute for Systems Genomics, University of Connecticut , Storrs , CT , USA.

出版信息

Mol Membr Biol. 2016 Mar;33(1-2):1-11. doi: 10.1080/09687688.2016.1213432. Epub 2016 Aug 18.

Abstract

Geranylgeranyl diphosphate is a 20-carbon isoprenoid phospholipid whose lipid moiety can be post-translationally incorporated into proteins to promote membrane association. The process of geranylgeranylation has been implicated in anti-proliferative effects of clinical agents that inhibit enzymes of the mevalonate pathway (i.e. statins and nitrogenous bisphosphonates) as well as experimental agents that deplete geranylgeranyl diphosphate. Inhibitors of geranylgeranyl diphosphate synthase are an attractive way to block geranylgeranylation because they possess a calcium-chelating substructure to allow localization to bone and take advantage of a unique position of the enzyme within the biosynthetic pathway. Here, we describe recent advances in geranylgeranyl diphosphate synthase expression and inhibitor development with a particular focus on the molecular mechanisms that link geranylgeranyl diphosphate to cell proliferation via geranylgeranylated small GTPases.

摘要

香叶基香叶基二磷酸是一种含有20个碳原子的类异戊二烯磷脂,其脂质部分可在翻译后掺入蛋白质中以促进膜结合。香叶基香叶基化过程与抑制甲羟戊酸途径酶的临床药物(即他汀类药物和含氮双膦酸盐)以及消耗香叶基香叶基二磷酸的实验药物的抗增殖作用有关。香叶基香叶基二磷酸合酶抑制剂是阻断香叶基香叶基化的一种有吸引力的方法,因为它们具有钙螯合亚结构,可使其定位于骨骼,并利用该酶在生物合成途径中的独特位置。在此,我们描述了香叶基香叶基二磷酸合酶表达和抑制剂开发的最新进展,特别关注通过香叶基香叶基化的小GTP酶将香叶基香叶基二磷酸与细胞增殖联系起来的分子机制。

相似文献

1
Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation.
Mol Membr Biol. 2016 Mar;33(1-2):1-11. doi: 10.1080/09687688.2016.1213432. Epub 2016 Aug 18.
2
Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors.
Molecules. 2017 May 27;22(6):886. doi: 10.3390/molecules22060886.
3
Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.
Bioorg Med Chem. 2008 Jan 1;16(1):390-9. doi: 10.1016/j.bmc.2007.09.029. Epub 2007 Sep 18.
6
Geranylgeranyl diphosphate synthase: an emerging therapeutic target.
Clin Pharmacol Ther. 2011 Dec;90(6):804-12. doi: 10.1038/clpt.2011.215. Epub 2011 Nov 2.
7
Key Enzymes for the Mevalonate Pathway in the Cardiovascular System.
J Cardiovasc Pharmacol. 2021 Feb 1;77(2):142-152. doi: 10.1097/FJC.0000000000000952.
8
Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate.
J Pharmacol Exp Ther. 2011 May;337(2):540-6. doi: 10.1124/jpet.110.175521. Epub 2011 Feb 18.
9
The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease.
J Biol Chem. 2020 Apr 10;295(15):5152-5162. doi: 10.1074/jbc.REV119.008897. Epub 2020 Mar 5.
10
Structural Insight into Geranylgeranyl Diphosphate Synthase (GGDPS) for Cancer Therapy.
Mol Cancer Ther. 2024 Jan 3;23(1):14-23. doi: 10.1158/1535-7163.MCT-23-0358.

引用本文的文献

1
Engineering dimer mutants of human geranylgeranyl pyrophosphate synthase.
PLoS One. 2025 Jan 15;20(1):e0317437. doi: 10.1371/journal.pone.0317437. eCollection 2025.
2
α-Amino bisphosphonate triazoles serve as GGDPS inhibitors.
Bioorg Med Chem Lett. 2024 Apr 1;102:129659. doi: 10.1016/j.bmcl.2024.129659. Epub 2024 Feb 17.
3
Structural Insight into Geranylgeranyl Diphosphate Synthase (GGDPS) for Cancer Therapy.
Mol Cancer Ther. 2024 Jan 3;23(1):14-23. doi: 10.1158/1535-7163.MCT-23-0358.
5
Implications on the Therapeutic Potential of Statins Modulation of Autophagy.
Oxid Med Cell Longev. 2021 Jul 30;2021:9599608. doi: 10.1155/2021/9599608. eCollection 2021.
7
Synergistic effect of graphene oxide and zoledronic acid for osteoporosis and cancer treatment.
Sci Rep. 2020 May 8;10(1):7827. doi: 10.1038/s41598-020-64760-4.
8
Regulation of the Notch-ATM-abl axis by geranylgeranyl diphosphate synthase inhibition.
Cell Death Dis. 2019 Sep 30;10(10):733. doi: 10.1038/s41419-019-1973-7.
9
ω-Hydroxy isoprenoid bisphosphonates as linkable GGDPS inhibitors.
Bioorg Med Chem Lett. 2019 Oct 1;29(19):126633. doi: 10.1016/j.bmcl.2019.126633. Epub 2019 Aug 20.
10
Preclinical investigation of a potent geranylgeranyl diphosphate synthase inhibitor.
Invest New Drugs. 2018 Oct;36(5):810-818. doi: 10.1007/s10637-018-0571-3. Epub 2018 Mar 2.

本文引用的文献

1
Potent Triazole Bisphosphonate Inhibitor of Geranylgeranyl Diphosphate Synthase.
ACS Med Chem Lett. 2015 Oct 28;6(12):1195-8. doi: 10.1021/acsmedchemlett.5b00334. eCollection 2015 Dec 10.
3
Variegated RHOA mutations in adult T-cell leukemia/lymphoma.
Blood. 2016 Feb 4;127(5):596-604. doi: 10.1182/blood-2015-06-644948. Epub 2015 Nov 16.
4
Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer Through GTPase Signaling Pathways.
Cancer Growth Metastasis. 2015 Oct 19;8(Suppl 1):95-113. doi: 10.4137/CGM.S29407. eCollection 2015.
6
Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Clin Cancer Res. 2015 Apr 15;21(8):1819-27. doi: 10.1158/1078-0432.CCR-14-3214.
7
The potential of targeting Ras proteins in lung cancer.
Expert Opin Ther Targets. 2015 Apr;19(4):451-4. doi: 10.1517/14728222.2014.1000304. Epub 2015 Jan 6.
8
A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin.
Sci Transl Med. 2014 Nov 19;6(263):263ra161. doi: 10.1126/scitranslmed.3010382.
9
Protein prenylation: enzymes, therapeutics, and biotechnology applications.
ACS Chem Biol. 2015 Jan 16;10(1):51-62. doi: 10.1021/cb500791f. Epub 2014 Dec 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验